Sp1111

ENDOSCOPY

Date
May 9, 2023
Explore related products in the following collection:

Society: AGA

This session brings Chinese speaking experts together to provide a broad overview highlighting the best of AGA programming at Digestive Disease Week® (DDW) 2023 for Chinese speaking audiences.

Speaker


Tracks

Related Products

Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for ACTIVATING TRANSCRIPTION FACTOR 6 ACCELERATES MICROBIOTA-DEPENDENT RISK FOR COLITIS-ASSOCIATED CANCER IN INFLAMMATORY BOWEL DISEASES
ACTIVATING TRANSCRIPTION FACTOR 6 ACCELERATES MICROBIOTA-DEPENDENT RISK FOR COLITIS-ASSOCIATED CANCER IN INFLAMMATORY BOWEL DISEASES
BACKGROUND AND AIMS: Chemoresistance is a major cause of colorectal cancer (CRC) recurrence and death. The critical role of gut microbiome in the efficacy of CRC chemotherapy remains unclear…